Comparative effectiveness research: An empirical study of trials registered in ClinicalTrials.gov

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Bourgeois, Florence T ^a,b   Murthy, Srinivas ^c   Mandl, Kenneth D ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DATA BASE; FUNDING; GOVERNMENT; MEDICAL LITERATURE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLACEBO EFFECT; PREVALENCE; SAFETY; UNITED STATES; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DEVICES; ECONOMICS; EMPIRICAL RESEARCH; FINANCIAL MANAGEMENT; HUMAN; INTERNET; METHODOLOGY; TREATMENT OUTCOME;

DRUG;

CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; EMPIRICAL RESEARCH; EQUIPMENT AND SUPPLIES; HUMANS; INTERNET; PHARMACEUTICAL PREPARATIONS; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

EID: 84855501488     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028820     Document Type: Article

References (33)

1. Federal Coordinating Council for Comparative Effectiveness Research (2009) Report to the President and the Congress. Washington, DC Department of Health and Human Services.
2. Sox HC, Helfand M, Grimshaw J, Dickersin K, Tovey D, et al. (2010) Comparative effectiveness research: challenges for medical journals. PLoS Med 7: e1000269.
3. Rawlins MD, (2004) NICE work-providing guidance to the British National Health Service. N Engl J Med 351: 1383-1385.
4. Steinbrook R, (2008) Saying no isn't NICE- the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359: 1977-1981.
5. Clement FM, Harris A, Li JJ, Yong K, Lee KM, et al. (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443.
6. Henry DA, Hill SR, Harris A, (2005) Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA 294: 2630-2632.
7. Tierney M, Manns B, (2008) Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ 178: 432-435.
8. (2009) U.S. House Appropriations Committee American Recovery and Reinvestment Act of 2009, HR, 111th Cong, 1st Sess.
9. Baicker K, Chandra A, Skinner JS, Wennberg JE, (2004) Who you are and where you live: how race and geography affect the treatment of medicare beneficiaries. Health Aff (Millwood) Suppl Web Exclusives pp. VAR33-44.
10. Mittler JN, Landon BE, Fisher ES, Cleary PD, Zaslavsky AM, (2010) Market variations in intensity of Medicare service use and beneficiary experiences with care. Health Serv Res 45: 647-669.
11. Institute of Medicine (2009) Initial National Priorities for Comparative Effectiveness Research. Washington, DC National Academies Press.
12. Bourgeois FT, Murthy S, Mandl KD, (2010) Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 153: 158-166.
13. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM, (2009) Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 6: e1000144.
14. U.S. National Institutes of Health ClinicalTrials.gov.
15. DeAngelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Med J Aust 181: 293-294.
16. Zarin DA, Tse T, (2008) Medicine. Moving toward transparency of clinical trials. Science 319: 1340-1342.
17. U.S. Food and Drug Administration Amendments Act of 2007 (2007) Public Law No pp. 105-185.
18. Hochman M, McCormick D, (2010) Characteristics of published comparative effectiveness studies of medications. JAMA 303: 951-958.
19. American College of Physicians (2008) Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 148: 956-961.
20. Alexander GC, Stafford RS, (2009) Does comparative effectiveness have a comparative edge? JAMA 301: 2488-2490.
21. Weinstein MC, Skinner JA, (2010) Comparative effectiveness and health care spending-implications for reform. N Engl J Med 362: 460-465.
22. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, et al. (2000) The uncertainty principle and industry-sponsored research. Lancet 356: 635-638.
23. Stafford RS, Wagner TH, Lavori PW, (2009) New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med 361: 1230-1233.
24. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 170: 477-480.
25. Ridker PM, Torres J, (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 295: 2270-2274.
26. Berger E, (2008) Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research. Ann Emerg Med 52: 137-139.
27. Smith R, (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2: e138.
28. Bero L, Oostvogel F, Bacchetti P, Lee K, (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 4: e184.
29. Vedula SS, Bero L, Scherer RW, Dickersin K, (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361: 1963-1971.
30. Lexchin J, Bero LA, Djulbegovic B, Clark O, (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170.
31. O'Connor AB, (2010) Building comparative efficacy and tolerability into the FDA approval process. JAMA 303: 979-980.
32. Sorenson C, Naci H, Cylus J, Mossialos E, (2011) Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ 343: d4849.
33. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, et al. (2009) Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 151: 206-209.